During the fourth congress of the European Academy of Neurology, held in Lisbon, Portugal, from June 16 to 19, researchers presented on the roles of both existing and investigational anti-CD20 drugs in treating neurological diseases.
During the fourth congress of the European Academy of Neurology (EAN), held in Lisbon, Portugal, from June 16 to 19, researchers presented on the roles of both existing and investigational anti-CD20 drugs in treating neurological diseases.
Rituximab may have a role in treating immunoglobulin G4-related disease
Rituximab has been demonstrated to be useful in the treatment of neurological diseases such as multiple sclerosis (MS) and myasthenia gravis, but a case study presented during the EAN conference suggests that it may also have a role to play in treating diseases related to immunoglobulin G4 (IgG4).
Researchers from Portugal reported on the case of a 70-year old man who developed progressive right ptosis and vision loss that was associated with headache.1 Magnetic resonance imaging (MRI) showed right frontal lobe hypersignal with homogeneous enhancement as well as meningeal thickening with dural enhancement. Computed tomography revealed ethmoidal and frontal bone erosion. A biopsy revealed a lymphoplasmacytic infiltrate, storiform fibrosis, and more than 10 IgG4-expressing plasma cells per field.
While corticosteroids were used with initial results, the patient experienced progressive deterioration of his vision as meningeal thickening increased. The patient then received 2 infusions of rituximab, after which he experienced improvement in his visual acuity (though MRI results remained unchanged).
According to the study’s authors, intravenous rituximab is a promising therapeutic strategy in treating IgG4-related disease in patients who do not have an adequate response to steroids, and intrathecal administration of rituximab may be a possibility in those who do not respond adequately to intravenous administration.
A novel anti-CD20 monoclonal antibody may allow for short infusion times in MS
While existing anti-CD20 drugs have demonstrated their utility in treating MS, lengthy infusion times may be burdensome for patients. In a phase 2 clinical trial, ublituximab, a novel anti-CD20 agent, was demonstrated to be safe and well tolerated when infused over time periods as low as 1 hour.2
The 52-week study included 24 patients with relapsing-remitting MS. Patients received 3 infusions of the investigational drug on days 1, 15, and week 24. All patients achieved 95% B-cell depletion within 4 weeks of treatment, and of the 11 patients who have so far completed 52 weeks of treatment, 87% remain relapse-free and 81% are free of disability progression.
The most commonly reported adverse events (AEs) were infusion site reactions, all of which were grade 1 or grade 2, which were reported in 17% of patients. No severe AEs were reported, and infusions times as low as 1 hour were not associated with an increase in AEs.
References
1. Soares C, Costa A, Pestana-Silva R, Faria O, Honavar M, Abreu P. A difficult case of immunoglobulin G4-hypertrophic pachymeningitis—rituximab as part of the solution. Presented at the European Academy of Neurology Congress, June 16-19, 2018; Lisbon, Portugal. Abstract EPR2143. https://ipp-ean18.netkey.at/index.php?p=recorddetail&rid=ed524a8c-f503-4bc5-9c97-ba95fa64edf7&t=browsepresentations.
2. Fox E, Lovett-Racke A, Inglese M, et al. Phase 2 multicenter study results of ublituximab, a novel glycoengineered antiCD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS). Presented at the European Academy of Neurology Congress, June 16-19, 2018; Lisbon, Portugal. Abstract O331. https://ipp-ean18.netkey.at/index.php?p=recorddetail&rid=cf7552fb-319c-4ba5-a646-f130ca9def7c&t=browsepresentations.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.